Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
Sorafenib is a multikinase inhibitor which is acting on various cellular pathways involved in
 the genesis of acute myeloid leukemia (AML). Sorafenib is therefore a promising candidate for
 improvement of chemotherapy results in AML. This clinical trial evaluates the efficacy of
 sorafenib added to standard chemotherapy for AML in patients between 18 and 60 years of age.
 Patients are randomised to receive either sorafenib capsules or placebo in addition to their
 chemotherapy. The placebo and the sorafenib group will be compared regarding event-free
 survival and other clinical outcomes. An event is either treatment failure or relapse or
 death. According to the study hypothesis, the sorafenib group will have less events than the
 placebo group.
Inclusion criteria:

 -  Patients with newly diagnosed AML (except APL) according to the FAB and WHO
 classification, including AML evolving from MDS or other hematologic diseases and AML
 after previous cytotoxic therapy or radiation (secondary AML)

 -  Bone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or
 differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of
 nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by
 cytogenetic aberrations, the proportion of blasts may be < 20%.

 -  Age ≥ 18 and ≤ 60 years

 -  Informed consent, personally signed and dated to participate in the study

 -  ECOG performance status of 0-1

 -  Life expectancy of at least 12 weeks

 -  Adequate liver and renal function as assessed by laboratory requirements to be
 conducted within 7 days prior to Screening

 Exclusion criteria:

 -  Patients who are not eligible for standard chemotherapy as per discretion of the
 treating physician

 -  Central nervous system manifestation of AML

 -  Cardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI
 more than 6 months prior to study entry is permitted); serious cardiac ventricular
 arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

 -  Chronically impaired renal function (creatinine clearance < 30 ml/min)
 (Cockcroft-Gault formula)

 -  Patients undergoing renal dialysis

 -  Chronic pulmonary disease with relevant hypoxia

 -  Known HIV and/or hepatitis C infection

 -  Evidence or history of severe non-leukemia associated bleeding diathesis or
 coagulopathy

 -  Evidence or recent history of CNS disease, including primary or metastatic brain
 tumors, seizure disorders

 -  Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or
 diastolic 95 mmHg

 -  Any severe concomitant condition which makes it undesirable for the patient to
 participate in the study or which could jeopardize compliance of the protocol

 -  Patients with major surgery, open biopsy or significant traumatic injury within 4
 weeks of start of first dose

 -  Serious, non-healing wound, ulcer or bone fracture

 -  Uncontrolled active infection > Grade 2 NCI-CTC version 3.0

 -  Concurrent malignancies other than AML

 -  History of organ allograft

 -  Allergy to study medication or excipients in study medication